(Q42651626)

English

Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

macular degeneration

1 reference

based on heuristic

inferred from title

author name string

Leigh Spielberg

1

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Anita Leys

2

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

publication date

4 March 2010

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Graefe's Archive for Clinical and Experimental Ophthalmology

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

248

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

943-956

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00417-009-1256-6

21 January 2018

Factors controlling ocular angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS00417-009-1256-6

21 January 2018

Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys

1 reference

https://api.crossref.org/works/10.1007%2FS00417-009-1256-6

21 January 2018

Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study.

1 reference

https://api.crossref.org/works/10.1007%2FS00417-009-1256-6

21 January 2018

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current concepts in the pathogenesis of age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination therapy for choroidal neovascularisation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of treatment parameters on selectivity of verteporfin therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequence of Early Vascular Events after Photodynamic Therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlation in foveal thickness measurements between spectral-domain and time-domain optical coherence tomography in normal individuals.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms of retinal and choroidal neovascularization

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidance for the treatment of neovascular age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effects of a flexible visual acuity-driven ranibizumab treatment regimen in age-related macular degeneration: outcomes of a drug and disease model

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination treatment with reduced-fluence photodynamic therapy and intravitreal injection of triamcinolone for subfoveal choroidal neovascularization in macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective comparison of cirrus and stratus optical coherence tomography for quantifying retinal thickness

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optical coherence tomography-based decision making in exudative age-related macular degeneration: comparison of time- vs spectral-domain devices

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ranibizumab for neovascular age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of growth factors and the wound healing response in age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ranibizumab according to need: a treatment for age-related macular degeneration

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination therapy for the treatment of ocular neovascularization

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ranibizumab: Phase III clinical trial results

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Early antiexudative response--OCT monitoring after intravitreal bevacizumab injection]

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey

1 reference

https://pubmed.ncbi.nlm.nih.gov/20204659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00417-009-1256-6

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42651626&oldid=2205580489"